Fasting, Caloric Restriction Hormone Boosts Healthspan

Caloric Restriction and Fasting: A Newly Discovered Hormone Mechanism for Healthspan

Researchers from UCSF identified a specific molecular pathway, triggered by fasting and caloric restriction, that improves healthspan independently of lifespan. The work clarifies a decades-old observation: dietary restriction makes organisms healthier for longer, and a steroid hormone called ADIOL appears to be a key orchestrator of those benefits.

The ADIOL Hormone: A Direct Link Between Fasting and Cellular Health

The 2026 study in Aging Cell from the University of California, San Francisco, provides a mechanistic breakthrough. Using the nematode C. elegans, the team led by Kaveh Ashrafi found that fasting and caloric restriction activate a precise signaling axis. It begins with the increased production of ADIOL, a steroid hormone discovered in humans nearly a century ago but with poorly defined functions.

This hormone then binds to and activates a nuclear hormone receptor called NHR-91, a homolog of the human estrogen receptor β. The activated receptor initiates a genetic program that results in a specific change: a reduction in kynurenic acid. Kynurenic acid is a neuromodulatory metabolite; imbalances in its pathway are implicated in neuroinflammation and age-related brain disorders. By lowering its levels, the ADIOL-NHR-91 axis improves markers of healthspan, such as stress resistance and neuronal function. Crucially, administering ADIOL alone was sufficient to replicate these benefits, while blocking its production nullified the effects of fasting.

Healthspan Gains Are Separate from Lifespan Extension

A critical distinction emerged from this research. While the ADIOL pathway was essential for the healthspan improvements seen with dietary restriction, it did not extend the organism’s maximum lifespan. “ADIOL does not extend lifespan, indicating its healthspan benefits are independent of longevity,” the authors state. This separation suggests aging involves multiple, parallel processes. One set of mechanisms, perhaps related to fundamental damage repair, may govern longevity. Another set, exemplified by the ADIOL-kynurenine pathway, governs functional capacity and resilience—the quality of life during the aging process. You can read a deeper exploration of this finding in our article on Fasting ADIOL Hormone Boosts Healthspan, Not Longevity.

The Human Context: Promising Signals, But Proof Is Pending

How does this worm biology translate to humans? A separate 2026 perspective in Biogerontology by Matthew Steinhauser and Pouneh Fazeli at the University of Pittsburgh addresses this gap. They note humans possess “evolved adaptive mechanisms that enable survival even with zero calories for periods of months or longer.” Intermittent exposure to the metabolic stress of fasting may activate beneficial pathways, “although such benefits have not been proven in humans” for longevity.

The authors conclude the current evidence is “limited and not sufficient to justify widespread adoption of fasting practices, nor is it sufficient to exclude the possibility that fasting holds a key to a longer life.” Their position is pragmatic: for a motivated patient who is overweight or obese and lacks specific risk factors like frailty or a history of eating disorders, a trial of intermittent fasting for weight loss and metabolic health is reasonable. The ultimate goal, however, is to move beyond difficult dietary adherence. “Incorporation of mechanistic and multi-omics endpoints will be critical to understand potential mechanisms of benefit in humans,” they write, with the aim of developing a “fasting mimetic drug.”

From Mechanism to Practice and Future Drugs

The convergence of these two studies points to a clear trajectory for fasting science. First, model organisms like C. elegans are revealing specific, druggable pathways—like ADIOL and its receptor—that mediate the health benefits of reduced calorie intake. Second, human research must now use advanced profiling to confirm if similar pathways are activated in people during fasting protocols.

For current practice, the Pittsburgh researchers’ framework is the most evidence-based. Time-restricted eating or intermittent fasting can be a tool for improving metabolic parameters like insulin sensitivity and promoting weight loss. It should be approached with awareness of individual context, not as a universal longevity elixir. The most exciting practical implication is that identifying these core mechanisms could lead to pharmacological interventions. A compound that safely activates the ADIOL receptor or lowers kynurenic acid could theoretically offer healthspan benefits without the challenge of constant calorie counting or fasting windows, similar to how the drug rapamycin is studied for its mTOR-inhibiting effects. For more on that approach, see our analysis of the Rapamycin + Exercise Trial.

Fasting and caloric restriction research is moving from observing effects to dissecting causes. The discovery of the ADIOL pathway provides a concrete molecular target linking dietary stress to improved cellular health. While applying fasting for human longevity remains a hypothesis, its role in metabolic health is clearer, and the pursuit of its mimetics is now grounded in a specific biological mechanism.

Sources:
https://pubmed.ncbi.nlm.nih.gov/42043665/
https://pubmed.ncbi.nlm.nih.gov/42021510/
https://pubmed.ncbi.nlm.nih.gov/41889977/